CN103524620A - 成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法 - Google Patents

成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法 Download PDF

Info

Publication number
CN103524620A
CN103524620A CN201310384769.3A CN201310384769A CN103524620A CN 103524620 A CN103524620 A CN 103524620A CN 201310384769 A CN201310384769 A CN 201310384769A CN 103524620 A CN103524620 A CN 103524620A
Authority
CN
China
Prior art keywords
antibody
fgfr
cell
people
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310384769.3A
Other languages
English (en)
Chinese (zh)
Inventor
H·孙
L·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of CN103524620A publication Critical patent/CN103524620A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201310384769.3A 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法 Pending CN103524620A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
US61/196,855 2008-10-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980141656.2A Division CN102186884B (zh) 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3（fgfr-3）抑制物

Publications (1)

Publication Number Publication Date
CN103524620A true CN103524620A (zh) 2014-01-22

Family

ID=42062445

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310384769.3A Pending CN103524620A (zh) 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法
CN200980141656.2A Expired - Fee Related CN102186884B (zh) 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3（fgfr-3）抑制物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980141656.2A Expired - Fee Related CN102186884B (zh) 2008-10-20 2009-10-15 成纤维细胞生长因子受体-3（fgfr-3）抑制物

Country Status (17)

Country Link
US (3) US8043618B2 (2)
EP (1) EP2342232A2 (2)
JP (1) JP5577345B2 (2)
KR (1) KR101370798B1 (2)
CN (2) CN103524620A (2)
AR (1) AR073770A1 (2)
AU (1) AU2009307841B2 (2)
BR (1) BRPI0919832A8 (2)
CA (1) CA2741127C (2)
EA (1) EA021584B1 (2)
IL (1) IL211807A0 (2)
MX (1) MX2011004317A (2)
NZ (1) NZ592369A (2)
TW (1) TWI381848B (2)
UA (1) UA101681C2 (2)
WO (1) WO2010048026A2 (2)
ZA (1) ZA201101938B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114015770A (zh) * 2021-12-30 2022-02-08 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
AU2015236073B2 (en) 2014-03-25 2020-04-30 Regeneron Pharmaceuticals, Inc. FGF21 receptor agonists and uses thereof
US20170101466A1 (en) * 2014-06-03 2017-04-13 Masahisa Handa Anti-blys antibodies
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
KR20170048560A (ko) * 2014-09-05 2017-05-08 하이퍼파인 리서치, 인크. 낮은 필드 자기 공명 이미징 방법들 및 장치
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
BR112017017700A2 (pt) * 2015-02-19 2018-07-31 Bioclin Therapeutics Inc métodos, composições e kits para tratamento do câncer
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
TW201833140A (zh) * 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
CA3189470A1 (en) 2020-08-21 2022-02-24 Yves SABBAGH Fgfr3 antibodies and methods of use
KR20250116795A (ko) * 2022-11-14 2025-08-01 리제너론 파마슈티칼스 인코포레이티드 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
KR20250148746A (ko) 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1697420A2 (en) 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
MX2008014978A (es) * 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
EP2450377A1 (en) * 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
ES2453592T3 (es) * 2007-08-02 2014-04-08 Novimmune Sa Anticuerpos anti-RANTES y métodos de uso de los mismos
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114015770A (zh) * 2021-12-30 2022-02-08 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用

Also Published As

Publication number Publication date
CN102186884A (zh) 2011-09-14
MX2011004317A (es) 2011-06-24
KR20110056554A (ko) 2011-05-30
AR073770A1 (es) 2010-12-01
EA201170590A1 (ru) 2011-10-31
JP5577345B2 (ja) 2014-08-20
ZA201101938B (en) 2012-08-29
TWI381848B (zh) 2013-01-11
AU2009307841A1 (en) 2010-04-29
WO2010048026A3 (en) 2010-07-15
JP2012505912A (ja) 2012-03-08
US20120219563A1 (en) 2012-08-30
CA2741127C (en) 2015-06-02
US8182815B2 (en) 2012-05-22
AU2009307841B2 (en) 2013-09-12
BRPI0919832A8 (pt) 2019-01-08
KR101370798B1 (ko) 2014-03-14
NZ592369A (en) 2013-02-22
US8404240B2 (en) 2013-03-26
UA101681C2 (ru) 2013-04-25
US8043618B2 (en) 2011-10-25
WO2010048026A2 (en) 2010-04-29
IL211807A0 (en) 2011-06-30
TW201026325A (en) 2010-07-16
CA2741127A1 (en) 2010-04-29
EA021584B1 (ru) 2015-07-30
US20100098696A1 (en) 2010-04-22
EP2342232A2 (en) 2011-07-13
CN102186884B (zh) 2014-08-13
US20120009200A1 (en) 2012-01-12
BRPI0919832A2 (pt) 2015-12-15

Similar Documents

Publication Publication Date Title
CN103524620A (zh) 成纤维细胞生长因子受体-3(fgfr-3)抑制物和治疗的方法
JP6960485B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
CN114040926A (zh) 结合cd123的多肽及其用途
KR20130060223A (ko) 상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
NZ724649A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
CN114127115A (zh) 结合CLEC12a的多肽及其用途
JP7843824B2 (ja) 抗体および使用方法
CN114040927A (zh) 结合cd33的多肽及其用途
JP2022529232A (ja) 抗ｈｅｒ２結合分子
WO2020228604A1 (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
KR20220157686A (ko) 항-bcam 항체 또는 그의 항원 결합 단편
CN112272564B (zh) 可标靶vegfr2与vegfr3的双功能抗体
CN109476757A (zh) 抗-axl受体酪氨酸激酶抗体及其用途
CA3231586A1 (en) D3-binding molecules and uses thereof
WO2025026333A1 (en) Antibody against fgfr2b, method for preparing the same, and use thereof
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
TW202547875A (zh) 靶向成纖維細胞生長因子受體2IIIb的抗體及其應用
CN118496364A (zh) uPARAP特异性结合蛋白及其制备方法和应用
Kamat Combined use of multiple monoclonal antibodies targeting epidermal growth factor receptor for improved cancer therapeutics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140122